These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10498204)

  • 1. Aminoisoquinolines: design and synthesis of an orally active benzamidine isostere for the inhibition of factor XA.
    Choi-Sledeski YM; Becker MR; Green DM; Davis R; Ewing WR; Mason HJ; Ly C; Spada A; Liang G; Cheney D; Barton J; Chu V; Brown K; Colussi D; Bentley R; Leadley R; Dunwiddie C; Pauls HW
    Bioorg Med Chem Lett; 1999 Sep; 9(17):2539-44. PubMed ID: 10498204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, synthesis, and SAR of monobenzamidines and aminoisoquinolines as factor Xa inhibitors.
    Zhang P; Zuckett JF; Woolfrey J; Tran K; Huang B; Wong P; Sinha U; Park G; Reed A; Malinowski J; Hollenbach S; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1657-61. PubMed ID: 12039584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amido-(propyl and allyl)-hydroxybenzamidines: development of achiral inhibitors of factor Xa.
    Gong Y; Pauls HW; Spada AP; Czekaj M; Liang G; Chu V; Colussi DJ; Brown KD; Gao J
    Bioorg Med Chem Lett; 2000 Feb; 10(3):217-21. PubMed ID: 10698439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and SAR of benzamidine factor Xa inhibitors containing a vicinally-substituted heterocyclic core.
    Fevig JM; Pinto DJ; Han Q; Quan ML; Pruitt JR; Jacobson IC; Galemmo RA; Wang S; Orwat MJ; Bostrom LL; Knabb RM; Wong PC; Lam PYS ; Wexler RR
    Bioorg Med Chem Lett; 2001 Mar; 11(5):641-5. PubMed ID: 11266160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonbenzamidine tetrazole derivatives as factor Xa inhibitors.
    Quan ML; Ellis CD; He MY; Liauw AY; Woerner FJ; Alexander RS; Knabb RM; Lam PY; Luettgen JM; Wong PC; Wright MR; Wexler RR
    Bioorg Med Chem Lett; 2003 Feb; 13(3):369-73. PubMed ID: 12565931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand.
    Choi-Sledeski YM; Kearney R; Poli G; Pauls H; Gardner C; Gong Y; Becker M; Davis R; Spada A; Liang G; Chu V; Brown K; Collussi D; Leadley R; Rebello S; Moxey P; Morgan S; Bentley R; Kasiewski C; Maignan S; Guilloteau JP; Mikol V
    J Med Chem; 2003 Feb; 46(5):681-4. PubMed ID: 12593648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of benzamidine-type inhibitors of factor Xa.
    Gabriel B; Stubbs MT; Bergner A; Hauptmann J; Bode W; Stürzebecher J; Moroder L
    J Med Chem; 1998 Oct; 41(22):4240-50. PubMed ID: 9784099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The de novo design and synthesis of cyclic urea inhibitors of factor Xa: initial SAR studies.
    Galemmo RA; Maduskuie TP; Dominguez C; Rossi KA; Knabb RM; Wexler RR; Stouten PF
    Bioorg Med Chem Lett; 1998 Oct; 8(19):2705-10. PubMed ID: 9873607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and testing of amino-bicycloaryl based orally bioavailable thrombin inhibitors.
    Rewinkel JB; Lucas H; Smit MJ; Noach AB; van Dinther TG; Rood AM; Jenneboer AJ; van Boeckel CA
    Bioorg Med Chem Lett; 1999 Oct; 9(19):2837-42. PubMed ID: 10522702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The design of competitive, small-molecule inhibitors of coagulation factor Xa.
    Pauls HW; Ewing WR
    Curr Top Med Chem; 2001 Jun; 1(2):83-100. PubMed ID: 11899252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and biological activity of YM-60828 derivatives: potent and orally-bioavailable factor Xa inhibitors based on naphthoanilide and naphthalensulfonanilide templates.
    Hirayama F; Koshio H; Ishihara T; Watanuki S; Hachiya S; Kaizawa H; Kuramochi T; Katayama N; Kurihara H; Taniuchi Y; Sato K; Sakai-Moritani Y; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2002 Aug; 10(8):2597-610. PubMed ID: 12057649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.
    Pinto DJ; Orwat MJ; Wang S; Fevig JM; Quan ML; Amparo E; Cacciola J; Rossi KA; Alexander RS; Smallwood AM; Luettgen JM; Liang L; Aungst BJ; Wright MR; Knabb RM; Wong PC; Wexler RR; Lam PY
    J Med Chem; 2001 Feb; 44(4):566-78. PubMed ID: 11170646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants.
    Lam PY; Clark CG; Li R; Pinto DJ; Orwat MJ; Galemmo RA; Fevig JM; Teleha CA; Alexander RS; Smallwood AM; Rossi KA; Wright MR; Bai SA; He K; Luettgen JM; Wong PC; Knabb RM; Wexler RR
    J Med Chem; 2003 Oct; 46(21):4405-18. PubMed ID: 14521405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and SAR of amino acid derivatives as factor Xa inhibitors.
    Su T; Wu Y; Doughan B; Jia ZJ; Woolfrey J; Huang B; Wong P; Park G; Sinha U; Scarborough RM; Zhu BY
    Bioorg Med Chem Lett; 2001 Nov; 11(22):2947-50. PubMed ID: 11677132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, and biological activity of novel factor Xa inhibitors: 4-aryloxy substituents of 2,6-diphenoxypyridines.
    Ng HP; Buckman BO; Eagen KA; Guilford WJ; Kochanny MJ; Mohan R; Shaw KJ; Wu SC; Lentz D; Liang A; Trinh L; Ho E; Smith D; Subramanyam B; Vergona R; Walters J; White KA; Sullivan ME; Morrissey MM; Phillips GB
    Bioorg Med Chem; 2002 Mar; 10(3):657-66. PubMed ID: 11814853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetrahydro-isoquinoline-based factor Xa inhibitors.
    Kucznierz R; Grams F; Leinert H; Marzenell K; Engh RA; von der Saal W
    J Med Chem; 1998 Dec; 41(25):4983-94. PubMed ID: 9836616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and structure-activity relationships of amidine-substituted (bis)benzylidene-cycloketone olefin isomers as potent and selective factor Xa inhibitors.
    Guilford WJ; Shaw KJ; Dallas JL; Koovakkat S; Lee W; Liang A; Light DR; McCarrick MA; Whitlow M; Ye B; Morrissey MM
    J Med Chem; 1999 Dec; 42(26):5415-25. PubMed ID: 10639283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel, potent and selective chimeric FXa inhibitors featuring hydrophobic P1-ketoamide moieties.
    Semple JE; Levy OE; Minami NK; Owens TD; Siev DV
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2305-9. PubMed ID: 11055344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological activity of non-basic compounds as factor Xa inhibitors: SAR study of S1 and aryl binding sites.
    Komoriya S; Haginoya N; Kobayashi S; Nagata T; Mochizuki A; Suzuki M; Yoshino T; Horino H; Nagahara T; Suzuki M; Isobe Y; Furugoori T
    Bioorg Med Chem; 2005 Jun; 13(12):3927-54. PubMed ID: 15911309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological activity of potent and selective inhibitors of blood coagulation factor Xa.
    Willardsen JA; Dudley DA; Cody WL; Chi L; McClanahan TB; Mertz TE; Potoczak RE; Narasimhan LS; Holland DR; Rapundalo ST; Edmunds JJ
    J Med Chem; 2004 Jul; 47(16):4089-99. PubMed ID: 15267248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.